1. Home /
  2. Markets /
  3. Regulation

Regulation  

Chinese Tech Stocks Plunge on Tighter Access to U.S. Markets

Chinese companies looking to list overseas are contending with pressure from U.S. and Chinese regulators, with it impossible to satisfy both.

Chinese Regulators Summon Big Tech Who's Who for Showdown Talks

Thirteen Chinese tech firms have been told to change their ways by stopping anticompetitive practices and getting licenses for consumer credit.

Bye Bye Bitcoin?

Thursday's actions by the U.S. on Russia highlight how crypto makes it much easier for despots to avoid the impact of sanctions.

Investors to Suffer as Company Director Details Obscured in Hong Kong

The Hong Kong government wants to change public-record rules in a way that encourages fraud and abuse.

Time to Take Some Bitcoin Chips Off the Table

Here's what has me nervous now.

How to Stop Skyrocketing Share Prices? Let's Count the Ways

I fully expect some new regulation to come down from the market action of the past two weeks.

Bright Cannabis Outlook Leads to Bigger Estimates for 2022

The fundamentals of the cannabis industry continue to improve.

As New Biden Regulations Move Forward, There's Fallout in Some Sectors

This looks like consolidation after a big run rather than a major shift in market character.

Let's Grade the Social Media Stocks

Was Monday's price action much ado about nothing?

Alibaba May Need Magic Tricks to Aid in Bottoming

The risk is that all the gains since March could be wiped out.

With Alibaba on the Ropes, I'll Take a Pass

My feeling is that if one is into speculation, one can trade names like BABA.

Korean Stocks Make Run at Doubling on Margin Trading Fever

Household debt in South Korea stands at 100% of GDP as Koreans borrow like mad to buy stocks in a red-hot market where short selling is banned.

Pending Law Covering Foreign Company U.S. Listings Isn't Discriminatory

An act to improve the accounting compliance of foreign U.S.-listed companies doesn't mention China, and doesn't need to.

Why I'm Selling Boeing Shares

The plan is to take off what was a successful trade and reduce the risk, leaving an investment in place somewhat composed of 'house money'.

2021 Won't Be Like 2020 for Big Tech

There are three key reasons to think next year won't be a good as this year has been for the tech giants.

Nikola Drama Drags Other SPAC Names Downhill, Too

The popularity of special purpose acquisition companies has gotten the attention of the SEC, and now we have questions over FMCI's merger.

I Wouldn't Back Up the Truck for Nikola Stock Right Now

While I like getting involved in volatility, I don't see any edge here, only the potential to see things go ... rolling down hill.

China's Kingold Jewelry Allegedly Used Fake Gold to Secure Huge Loans

Lenders to the Nasdaq-listed jewelry maker reportedly have discoverd that 83 tons of gold used to borrow billions appear to be copper alloy bars.

Acreage Probe Leads Company to Reform Massachusetts Deals

Cannabis player came under scrutiny for number of store licenses in state.

Jim Cramer: The Earth's New Cop? The Microsoft Protection Agency

While the president is pushing coal, this corporate giant is stepping up to cut the carbon cord.

Under Armour Loses Traction and Puts Chart Support Into Question

Shares of the shoe and apparel maker are reacting to reduced revenue guidance and word of government investigations into its accounting practices.

The Cannabis Sector and Its Dot-Com Like Meltdown

Black-market vaping has made the entire cannabis group toxic.

Have Those Once-Smoking Cannabis Stocks Burnt Down to a Bottom?

Several watchers and market players are deep in the weeds, tracking short action and key companies like Canopy Growth, trying to find out whether the industry has turned over a new leaf.

These Drug Cos. Could Soon Feel Big Side Effects of Opioid Crisis

No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.

Johnson & Johnson Rises on $572 Million Fine That's Smaller Than Feared

Wall Street expects the healthcare giant can take the jolt from the penalty delivered by an Oklahoma judge in the state's opioid case against J&J.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

Why Macy's Is at Risk of Losing Its Shirt

Earnings misses, bad planning, and product-line execution problems are all hitting the retailer, but it's the macro woes that will also hurt its competitors.

Earnings to Tell Whether Cannabis' High Growth Story Is Going to Pot

After a 2018 high, marijuana stocks are gaining popularity again, but which ones are producing the most green for investors? Here are the charts.

A Look at Mylan's New Post-Merger Management

What new management means for Mylan shareholders moving forward.

Mylan Jumps on Deal With Pfizer to Form New Company

Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.